SNDXSyndax Pharmaceuticals, Inc.
What is the market doing?
The market is leaning against it: in a downtrend (−34% vs 200-day) and a crowded short (+20% of shares).
In a downtrend, below its 50- and 200-day averages. Oversold (RSI 15). Price is −34% vs its 200-day average.
A crowded short, settled Sep 30, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How SNDX is trading
Syndax Pharmaceuticals, Inc. is −11% over the past year while the S&P 500 is +16%: 27 points behind the market.
1-year return · S&P 500 +16%
- vs 200-day average
- −34%
vs 200-day average · a clear downtrend
- RSI (14)
- 15
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 47%
Below its 52-week high
Details›
- Last close2026-10-23
- $13.40
- 1 monthS&P 500 −0.94%
- −26%
- 1 yearS&P 500 +16%
- −11%
- 5 yearsS&P 500 +86%
- −24%
- vs 50-day average$17.78
- −25%
- 52-week high
- $25.15
- 52-week low
- $12.91
- Annualised volatility
- 62%
- Insider selling, net, 6 monthsForms 3/4/5 to 2026-10-22
- $152K
| Year | Return |
|---|---|
| 2026 (year to date) | −36% |
| 2025 | +59% |
| 2024 | −39% |
| 2023 | −15% |
| 2022 | +16% |
| 2021 | −1.6% |
| 2020 | +153% |
| 2019 | +97% |
| 2018 | −49% |
| 2017 | +22% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 6 of 10 | +3.9% |
| Feb | 10 | 7 of 10 | +8.0% |
| Mar | 10 | 6 of 10 | +5.4% |
| Apr | 10 | 3 of 10 | +0.36% |
| May | 10 | 3 of 10 | −2.8% |
| Jun | 10 | 6 of 10 | +3.6% |
| Jul | 11 | 6 of 11 | +0.56% |
| Aug | 11 | 6 of 11 | +9.5% |
| Sep | 11 | 5 of 11 | −3.1% |
| Oct | 11 | 2 of 11 | −9.7% |
| Nov | 10 | 6 of 10 | +4.6% |
| Dec | 10 | 5 of 10 | +3.6% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.